logo
Rabies is making a comeback: here's what you need to know

Rabies is making a comeback: here's what you need to know

Yahoo6 days ago
Cases of rabies, a viral and potentially fatal disease that primarily spreads through the bites or scratches of infected animals, have recently been reported around the Northeast.
This week, officials in the town of Westfield, New Jersey, issued a public health alert after two reports of bites associated with a raccoon that may be infected with rabies, put the surrounding communities on high alert.
Last week, New York's Nassau County Department of Health declared an imminent public health threat in response to the ongoing spread of rabies among wild and feral-domesticated animals in the county.
'The resurgence of rabies in Nassau County, with its high population density and after nearly a decade of absence, represents a serious and evolving public health concern,' Nassau County Health Commissioner Dr. Irina Gelman said in a release. 'This declaration allows us to respond to prevent further spread and protect the health and safety of Nassau County residents.'
The resurgence comes after the county had successfully eradicated the virus since 2016. Over the last year, the department has confirmed 25 rabid animals, including raccoons and feral cats. The department noted that surveillance data shows that the virus is circulating in the area.
"Let me be clear, there is no cause for alarm, as we have not yet received any reports of human transmission,' Gelman said, according People. 'However, the time for prevention is now."
The declaration comes as health authorities in nearby Suffolk County reported two cases of rabies — the first since 2009.
But, whether or not an uptick in new cases indicate that rabies is becoming more prevalent in the region is unclear right now.
The summer season has something to do with it, Stony Brook Children's Hospital Chief of Pediatric Infectious Diseases Division Dr. Sharon Nachman told News 12 Long Island.
"It is a question of where you are and what the season is, and certainly the summertime is always associated with more bites and more worries about rabies," she said. A large number of cases has also been reported in Queens.
Around 4,000 animal rabies cases are reported each year. The animals most frequently found with rabies in the U.S. are bats, skunks, raccoons, and foxes, the Centers for Disease Control and Prevention says.
Outside of the Northeast, there has been a rise in cases linked to bats, resulting in three rabies deaths in a period of just five weeks a couple of years ago, according to the Centers for Disease Control and Prevention. In 2021, five Americans died of rabies, the largest number in a decade.
Human-caused climate change has resulted in the expansion of vampire bats' habitat, and increased the risk of rabies in domestic animals, according to scientists.
This week, Denver Animal Protection warned that the public should be cautious after two bats tested positive for the rabies virus, 9 News reported.
Still, fewer than 10 people in the U.S. die from rabies each year. That's thanks to post-exposure care and the rabies vaccine. Nearly 100,000 people are vaccinated following a possible exposure each year. Treatment is nearly 100 percent effective if you get it after an exposure.
Initial rabies symptoms are similar to the flu, including fever, headache, and muscle aches. They can progress to neurological and physical symptoms, such as delirium, a fear of water, and seizures.
To prevent the risk of infection, there are several steps people can take. Make sure pets are up to date with their vaccines, stay away from wildlife, call animal control to remove stray animals from the neighborhoods, and wash any bites or scratches immediately with soap and water after possible exposures before seeking medical attention.
'Rabies is preventable through vaccination and pet owners should remember that the best protection is to vaccinate for rabies and license all pets with the town,' Westfield officials said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CDC Cuts Experts Out of Panels That Develop Vaccine Policy
CDC Cuts Experts Out of Panels That Develop Vaccine Policy

Bloomberg

time28 minutes ago

  • Bloomberg

CDC Cuts Experts Out of Panels That Develop Vaccine Policy

The US Centers for Disease Control and Prevention told physician groups, public health professionals and infectious disease experts that they will no longer be invited to help review vaccine data and develop recommendations, according to an email viewed by Bloomberg. The move marks an escalation in Health and Human Services Secretary Robert F. Kennedy Jr.'s efforts to assert control over the CDC's vaccine advisory process. Under the change, external experts will be excluded from the Advisory Committee on Immunization Practices' working groups — subcommittees that review data and develop policy recommendations — but they will still be able to participate in open public meetings.

Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use

Yahoo

time2 hours ago

  • Yahoo

Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use

Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 4 out of 5 atherosclerotic cardiovascular disease (ASCVD) patients do not reach guideline-recommended LDL-C target, reinforcing urgent need for more aggressive LDL-C lowering2-5 Twice-yearly Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainment EAST HANOVER, N.J., July 31, 2025 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia1. The FDA proactively requested the label update based on the robust LDL-C lowering data for PCSK9-targeting therapies. "This first-line label update reinforces Leqvio's proven ability to effectively lower LDL-C, a critical risk factor for heart disease," said Victor Bultó, President, US, Novartis. "With this new indication enabling Leqvio's use as monotherapy along with diet and exercise, we now have the potential to help even more patients achieve their LDL-C lowering goals earlier in their treatment journey." With its twice-yearly, health care provider-administered dosing, Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainment. This is a critical unmet need, as up to 80% of ASCVD patients in the US struggle to reach the LDL-C guideline-recommended target of <70 mg/dL2-5. This need is heightened by the latest 2025 ACC/AHA Joint Committee Clinical Practice Guideline for the Management of Patients with Acute Coronary Syndromes, which recommends more aggressive treatment to achieve LDL-C targets6. The updated label removes the requirement for Leqvio to be used on top of or in combination with statin therapy1. Other updates include revising "primary hyperlipidemia" to the more specific term of "hypercholesterolemia" throughout the label, to more accurately focus on LDL-C reduction1. *After an initial dose and another at three months. About LeqvioLeqvio is an injectable prescription medicine indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics. Important Safety InformationDo not use if you have had an allergic reaction to Leqvio or any of its ingredients. The most common side effects of Leqvio were injection site reaction (including pain, redness, and rash), arthralgia (joint pain), bronchitis (chest cold). These are not all the possible side effects of Leqvio. Ask your health care provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. Please click here for Leqvio full Prescribing Information. About Atherosclerotic Cardiovascular Disease (ASCVD)Cardiovascular disease (CVD) affects hundreds of millions of people and claims more lives globally than cancer, chronic lung disease and diabetes combined7. Around 80% of premature cardiovascular deaths can be prevented by addressing factors that cause or worsen accounts for 85% of all CV deaths5,9-11. Its burden in the US is greater than that of any other chronic diseases5,9-11. ASCVD is caused by the development and growth of plaques in the inner lining of the arteries12. The atherosclerotic plaque is mainly composed of low-density lipoprotein cholesterol (LDL-C) that accumulates over time13. Cumulative exposure to LDL-C can increase one's risk of cardiovascular events such as a heart attack or stroke12,13. About Novartis in Cardiovascular DiseaseAt Novartis, our mission is to ensure no heart is lost too soon. We envision a world where preventable CV deaths are no longer part of our lives. We're proud of the positive impact we've made over the past 40 years and remain dedicated to tackling the most challenging problems in CVD. Through cutting-edge science and technology, we are focusing on areas of high unmet need, including scaling our xRNA platform across multiple risk factors and pioneering breakthroughs for genetically driven CVD risk factors and common heart conditions, including atrial fibrillation. We also work with patients, healthcare professionals, and organizations around the world to improve CV care beyond medicine alone. Together, we can help people with CVD enjoy longer, healthier lives and more time with their loved ones. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About NovartisNovartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn US, X/Twitter US and Instagram. References Leqvio. Prescribing information. Novartis Pharmaceuticals Corp Cannon CP, de Lemos JA, Rosenson RS, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1060-1068. doi:10.1001/jamacardio.2021.1810 Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol. 2016;10(5):1109-1118. doi:10.1016/ Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1016/ Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;85(22):2135-2237. doi:10.1016/ American Heart Association. More than half of U.S. adults don't know heart disease is leading cause of death, despite 100-year reign. Published January 24, 2024. Accessed July 25, 2025. World Heart Federation. World Heart Report 2023: confronting the world's number one killer. Published May 20, 2023. Accessed July 25, 2025. World Health Organization. Cardiovascular diseases (CVDs). Published June 11, 2021. Accessed July 25, 2025. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-e220. doi:10.1161/CIR.0b013e31823ac046 Kim H, Kim S, Han S, et al. Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study. BMC Public Health. 2019;19(1):1112. doi:10.1186/s12889-019-7439-0 Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161(1):161-172. doi:10.1016/ Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(10):1141-1156. doi:10.1016/ ### Novartis Media Relations E-mail: Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: original content: SOURCE Novartis Pharmaceuticals Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Childhood vaccine exemption rates hit a record high, CDC data shows
Childhood vaccine exemption rates hit a record high, CDC data shows

Yahoo

time4 hours ago

  • Yahoo

Childhood vaccine exemption rates hit a record high, CDC data shows

The percentage of kids who didn't get their recommended childhood vaccines rose again last school year, continuing the post-pandemic trend of Americans opting out of vaccinations. During the 2024-25 school year, 4.1% of kindergartners — about 138,000 kids — had a vaccine exemption, surpassing the previous record high of 3.7% during the prior school year. Nearly all exemptions are listed as nonmedical, meaning the kids aren't getting vaccines for religious or other personal reasons. The data, reported Thursday by the Centers for Disease Control and Prevention, comes as 2025 has logged the highest number of measles cases in 33 years: 1,333 cases in 39 states. Dr. Richard Besser, president of the Robert Wood Johnson Foundation and former acting director of the CDC, said he expects the rate of vaccination exemptions to continue to rise as long as Robert F. Kennedy Jr. — a long-time anti-vaccine activist — is health and human services secretary. 'While these numbers are bad, they don't even begin to reflect the impact that Secretary Kennedy will have on future exemptions,' Besser said. 'No one has done more to instill fear and distrust of vaccines.' HHS spokesman Andrew Nixon said in an email, 'That couldn't be further from the truth.' 'Vaccination remains the most effective way to protect children from serious diseases like measles and whooping cough, which can lead to hospitalization and long-term health complications,' Nixon said, adding that a family's decision to vaccinate is 'a personal one.' Approximately 286,000 kindergartners last school year had no documentation that they'd ever had the measles-mumps-rubella vaccine, the CDC said. Those children were toddlers when the pandemic hit in 2020. The MMR vaccine is given in two doses beginning at age 1. Just 92.5% of kids had their MMR and polio shots last year, and 92.1% had been vaccinated against tetanus and whooping cough. Both percentages are decreases from the year before. 'A drop in coverage like that can make a huge difference for keeping a disease like measles at bay,' said Josh Michaud, an associate director within the Global Health Policy program at KFF, a nonpartisan health policy organization. 'Lower measles vaccination rates are a key driver for outbreaks like the ones we're seeing across many states this year.' Measles is one of the most contagious viruses on Earth. Generally, 95% of the community must be vaccinated against it to prevent outbreaks. While states have different vaccination requirements for attending public and most private schools, they generally include MMR, poliovirus and chickenpox vaccines, as well as DTaP, which covers diphtheria, tetanus and acellular pertussis (also called whooping cough). This article was originally published on Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store